User Evaluation of a Home-collection Kit for People With Diabetes
NCT06038669
Recruiting
Type 1 and Type 2 are the most common types of diabetes mellitus. Although the cause of Type 1 is different to Type 2, they can both lead to high blood glucose levels as the patient is unable to store and use sugar. The disease is an epidemic of the 21st century which is increasing, having a current prevalence of approximately 8%. Poor disease control is associated with a range of long-term health conditions which have a severe impact upon quality of life and are responsible for the increased m... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/27/2025
Locations: University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, Not set
Conditions: Diabetes
Register for Updates
Treatment of Retinal Detachment in People Who Have Not Had Cataract Surgery With Vitrectomy vs Vitrectomy and Cataract Removal
NCT06997874
Recruiting
Background and study aims The retina is the layer at the back of the eye that allows us to see. Sometimes, it can detach from the wall of the eye, causing a condition called rhegmatogenous retinal detachment (RRD), which leads to vision loss and requires surgery. The most common surgery for RRD is vitrectomy, but this can lead to complications like cataracts, which worsen over time and need to be removed with another surgery. Cataract surgery involves replacing the cloudy lens with a clear artif... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/27/2025
Locations: Buckinghamshire Healthcare NHS Trust, Aylesbury, Not set +26 locations
Conditions: Rhegmatogenous Retinal Detachment
Register for Updates
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083
Recruiting
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: University of Arkansas, Little Rock, Arkansas +108 locations
Conditions: Multiple Myeloma
Register for Updates
Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
NCT06617897
Recruiting
This study is a phase 3, prospective, single center, randomized, open label, controlled, parallel arm, interventional study to investigate the efficacy and safety of CSL511, in participants undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) with predicted intraoperative blood loss of greater than or equal to (\>=) 2 liter (L). Eligible participants will be randomized in a 1:1 ratio to 1 of 2 treatment arms, to receive CS... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: Basingstoke and North Hampshire Hospital, Basingstoke, Not set
Conditions: Acquired Fibrinogen Deficiency
Register for Updates
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738
Recruiting
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Clinical Trial Site, Tucson, Arizona +173 locations
Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Register for Updates
Lysosomal Acid Lipase (LAL) Deficiency Registry
NCT01633489
Recruiting
This is an observational, multi-center, international disease registry designed to collect longitudinal data and create a knowledge base that will be utilized to improve the care and treatment of patients with LAL Deficiency. Participation in the Registry by both physicians and patients is voluntary.
Gender:
ALL
Ages:
All
Trial Updated:
05/23/2025
Locations: Clinical Trial Site, Phoenix, Arizona +103 locations
Conditions: Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Acid Lipase Deficiency, LIPA Deficiency, LAL-Deficiency
Register for Updates
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
NCT05722886
Recruiting
DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Patients must have a cancer with an identified mutation. This could be found during routine testing or as part of another research programme. The DETERMINE trial will recruit adults, teenagers and children. If a drug is found to benefit a new patient group, the study team will work with the NHS and the Cancer Drugs Funds to see if these drugs c... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/23/2025
Locations: Belfast City Hospital, Belfast, Not set +26 locations
Conditions: Haematological Malignancy, Solid Tumour
Register for Updates
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)
NCT06489028
Recruiting
The aim of this clinical trial is to investigate the efficacy and safety of allo-APZ2-CVU, administered topically on therapy-resistant non-healing CVUs compared to placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: RHEACELL Clinical Trial Site, Hialeah, Florida +15 locations
Conditions: Venous Leg Ulcer
Register for Updates
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer (ASpiRE)
NCT07002320
Recruiting
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Oncology Institute of Southern Switzerland, Bellinzona, Not set +3 locations
Conditions: Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Register for Updates
Comparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication
NCT06049654
Recruiting
The VIVALL-2 study is a randomized trial to compare the self-expandable supra-annular Allegra and the balloon-expandable intra-annular Edwards transcatheter valve systems in patients with degenerated biological aortic surgical valve.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Not set +6 locations
Conditions: Aortic Valve Stenosis, Structural Valve Deterioration
Register for Updates
Genetic Carbohydrate Maldigestion as a Model to Study Food Hypersensitivity
NCT05795049
Recruiting
Irritable bowel syndrome (IBS) affects one in seven people with gastrointestinal (GI) symptoms. IBS strongly impacts quality of life, is a leading cause of work absenteeism, and consumes 0.5% of the healthcare annual budget. It manifests in women more than men with symptoms including abdominal pain, bloating, constipation (IBS-C), diarrhoea (IBS-D), and mixed presentations (IBS-M) (1). The development of therapeutic options is hampered by the poor understanding of the underlying cause of symptom... Read More
Gender:
ALL
Ages:
Between 5 years and 70 years
Trial Updated:
05/23/2025
Locations: Nottingham University Hospitals NHS Trust, Nottingham, Not set
Conditions: Irritable Bowel Syndrome (IBS), Sucrase Isomaltase Deficiency
Register for Updates
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
NCT06126731
Recruiting
PROMIZE is an open-label, multi-centre, single-arm, Phase I/II clinical trial, evaluating the safety, tolerability and anti-tumuor efficacy of an antibiotic combination and enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Oncolgy Institute of Southern Switzerland (IOSI), Bellinzona, Not set +1 locations
Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Register for Updates